Exosome & Stem Cell Resources for Medical Professionals

Not every stem cell vial is created equal — even when the label says the same cell count. The difference often comes down to population doubling level (PDL), the single...

The complete 2026 peptide landscape organized by regulatory tier. Covers FDA-approved peptide drugs (Semaglutide, Tirzepatide, Tesamorelin), the seven peptides recently recommended by the FDA Pharmacy Compounding Advisory Committee, traditionally compounded...

A category framework for licensed practitioners building a regenerative service line. Compares PRP, exosome biologics, and UCT-MSC stem cells services across regulatory framework, sourcing infrastructure, cost structure, operational requirements, and...

Wondering if stem cell therapy is right for you? A patient-focused eligibility guide covering who's typically a good fit, who's not, how the screening and consultation process works, cost expectations,...

Introducing Stem Nova Direct — the B2C companion platform to Stem Nova Network. This article walks through how the telehealth-based concierge model actually works, categories of consumer interest, the five-tier...

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, and MOTS-c for compounding pharmacy production. The votes are non-binding, no regulatory change has...

Stem Nova Network has expanded its wholesale catalog to include a full peptide product line — 146 SKUs across 10 categories, manufactured in a controlled cleanroom facility in Scottsdale, Arizona,...

A straight-answer financial breakdown for licensed practitioners evaluating regenerative biologics. Startup costs, wholesale acquisition pricing, per-session margin math, and three 12-month practice scenarios — exosome biologics and UCT-MSC services covered...

A letter from co-founders Dalton and Dillon Worley on the 2023 family phone call that pulled regenerative medicine out of the abstract — and the gaps in the market that...

A practical buyer's guide for licensed practitioners evaluating exosome and stem cell suppliers. Covers the seven most common credential misuses — from "FDA-approved" claims to cGMP vs. cGTP confusion —...

60 billion, 150 billion, 25 million — the numbers are everywhere in biologic marketing. But how many exosomes or stem cells do you actually need? The answer depends on manufacturing...

Longevity medicine has expanded well beyond hormone optimization and IV vitamins. Here's how licensed longevity and anti-aging physicians are evaluating UCT-MSC biologics — what the published research supports, what compliance...